# Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer

> **NCT03444844** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Five Eleven Pharma, Inc.** · enrollment: 60 (estimated)

## Conditions studied

- Prostate Cancer Recurrent
- Prostate Cancer

## Interventions

- **DRUG:** Ga-68 P16-093 PET/CT scan

## Key facts

- **NCT ID:** NCT03444844
- **Lead sponsor:** Five Eleven Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-05-10
- **Primary completion:** 2020-10-27
- **Final completion:** 2022-07
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2022-05-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03444844

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03444844, "Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03444844. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*